Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Jul 16 · below the Ichimoku cloud · RSI 38 · MACD below its signal
None of the 29 investors followed here reported a position in MEDIF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MEDIF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 8, 2026 | Bumby (Michael Scott)Director of Issuer | — | 176.8K | — |
| Jun 8, 2026 | Halyk (Christopher John)Director of Issuer | — | 98.2K | — |
| Jun 8, 2026 | Hunter (Gregory Edison)Senior Officer of Issuer | — | 183.2K | — |
| Jun 8, 2026 | Jameson (Emily)Director of Issuer | — | 98.2K | — |
| Jun 8, 2026 | Medland (John)Director of Issuer | — | 88.4K | — |
| Jun 8, 2026 | Pidduck (David)Director of Issuer | — | 302.1K | — |
| Jun 8, 2026 | Taves (Christopher David)Director of Issuer | — | 392.9K | — |
| Jun 8, 2026 | Taves (Christopher David)Director of Issuer | Disposition in the public market at price 0.05 per share. | 176.8K | $9.55K |
| Dec 31, 2025 | Bumby (Michael Scott)Director of Issuer | — | 0 | — |
| Dec 8, 2025 | Bumby (Michael Scott)Director of Issuer | — | 83K | — |
| Dec 8, 2025 | Halyk (Christopher John)Director of Issuer | — | 83K | — |
| Dec 8, 2025 | Hunter (Gregory Edison)Senior Officer of Issuer | — | 589.4K | — |
| Dec 8, 2025 | Jameson (Emily)Director of Issuer | — | 32.6K | — |
| Dec 8, 2025 | Medland (John)Director of Issuer | — | 32.6K | — |
| Dec 8, 2025 | Pidduck (David)Director of Issuer | — | 1.31M | — |
| Dec 8, 2025 | Potts (Shelley Donne)Director of Issuer | — | 74.7K | — |
| Dec 8, 2025 | Strachan (Keith)Director of Issuer | — | 313.1K | — |
| Dec 8, 2025 | Taves (Christopher David)Director of Issuer | — | 392.9K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.0 | 6.0 | -13.2 | 45.7 | -14.9 | -10.5 | 5.9 | 5.6 | -10.5 | -5.9 | −5.9% | ||
| 2025 | 12.2 | 4.3 | 39.6 | -4.5 | -9.4 | -13.8 | 2.0 | 11.8 | 0.0 | 1.8 | -27.6 | 21.4 | +24.4% |
| 2024 | 6.1 | -5.8 | 28.6 | 9.5 | -15.9 | -5.2 | -3.6 | -11.3 | 6.4 | 4.0 | -7.7 | -14.6 | −16.3% |
| 2023 | 24.5 | -4.9 | -12.1 | 7.8 | -7.3 | -9.8 | -4.3 | 45.5 | -17.2 | 0.0 | -9.4 | 2.1 | +0.0% |
| 2022 | 9.6 | -20.0 | 16.4 | -35.6 | -35.4 | -9.7 | 16.1 | -16.9 | -1.9 | 11.3 | 8.5 | -23.4 | −66.4% |
| 2021 | 3.0 | -29.7 | 2.7 | 22.7 | -19.1 | -6.7 | -22.2 | -25.2 | 3.0 | -21.6 | -10.4 | −71.0% |
No analyst coverage for this instrument.
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower, pre-roll, and other cannabis products. In addition, the company offers cannabis related medical information and services; and cannabis clinic services for patients requiring medical cannabis education and prescriptions. MediPharm Labs Corp. was founded in 2015 and is based in Barrie, Canada.